Does Molecular Profiling of <i>KRAS</i>-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning?

Does Molecular Profiling of <i>KRAS</i>-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning?

Background: Several studies suggest that patients with <i>KRAS</i>-mutant NSCLC fail to benefit from standard systemic therapies and do not respond to EGFR inhibitors. Most recently, <i>KRAS</i> 12c data suggest specific treatment for improving ORR and OS. There is a clear ne...

Full description

Bibliographic Details
Main Authors: Nagla Abdel Karim, Asad Ullah, Peterson Pathrose, Hassana Fathallah, Ashley Perry, John C. Morris, Jiang Wang, Sandra L. Starnes
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Current Oncology
Subjects:
systemic therapy
mutations
molecular profiling
Online Access:https://www.mdpi.com/1718-7729/29/7/379

Internet

https://www.mdpi.com/1718-7729/29/7/379

Similar Items